Philogen S.p.A.

Equities

PHIL

IT0005373789

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-06-07 am EDT			5-day change	1st Jan Change
20.6 ^EUR	-1.44%		-2.83%	+11.35%

Jun. 06	Futures up slightly on ECB day	AN
Jun. 05	Mib bullish ahead of ECB; STM and Nexi soar	AN

Philogen S p A : Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al primo trimestre 2021

July 02, 2021 at 01:33 pm EDT

Press Releases

Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al primo trimestre 2021

May 12, 2021

Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al primo trimestre 2021, positiva pari a euro 104.668 migliaia, e prende atto dello stato di avanzamento dei trials principali Nidlegy™ e Fibromun in linea con le tempistiche previste (Price Sensitive)

Last Press Releases

Jul20212

Philogen Announces R&D Program Update

Jun202129

Deposito del Verbale dell'Assemblea degli Azionisti (Price sensitive)

Attachments

Original document
Permalink

Disclaimer

Philogen S.p.A. published this content on 02 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 July 2021 17:32:22 UTC.

Latest news about Philogen S.p.A.

Futures up slightly on ECB day	Jun. 06	AN
Mib bullish ahead of ECB; STM and Nexi soar	Jun. 05	AN
Mib rises; ECB could push cyclical stocks up	Jun. 05	AN
Mib up at start, DiaSorin good on FDA news	Jun. 05	AN
Indices expected to rise before PMIs	Jun. 05	AN
Mib bearish; Brunello Cucinelli the best	Jun. 04	AN
Mib falls in 34,100 area dragged by banks	Jun. 04	AN
Mib pegs 34,300; banking segment well	May. 30	AN
Mib veers upward; ERG takes top spot	May. 30	AN
Sales in Milan; but Philogen is at annual peak	May. 29	AN
Futures down; Brent advances to USD84 area	May. 29	AN
Mib in the red; BPER and Intesa resist declines	May. 28	AN
Mib down but Iveco and Pirelli soar	May. 24	AN
Philogen, NFP and liquidity drop in first quarter	May. 07	AN
Indices up; Italy, industrial sales down	Apr. 12	AN
Transcript : Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024	Apr. 03
Philogen reduces loss in 2023; NFP remains positive	Mar. 27	AN
Philogen S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Mib re-emerges in green; Saipem resumes rally	Mar. 07	AN
Futures await lists in red	Feb. 27	AN
Europeans down; Sogefi flies in Piazza Affari.	Feb. 26	AN
Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma	Feb. 20	CI
Mib in the red at 31,600; TIM still on top	Feb. 19	AN
European indexes down; TIM tops Mib	Feb. 19	AN
Futures bullish; PMI data coming in.	Jan. 24	AN

Chart Philogen S.p.A.

Duration

Period

More charts

Company Profile

Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.

Sector

Biotechnology & Medical Research

Calendar

2024-06-07 - Chemical Biology Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Philogen S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.6 EUR

Average target price

23.5 EUR

Spread / Average Target

+14.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHILOGEN S.P.A.	+11.35%	897M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs